Market News Archive
Stay updated with the latest announcements
PHOENIXFIN: Q1 Financials
(Q1 Un-audited): EPS was Tk. (4.03) for January-March 2026 as against Tk. (7.81) for January-March 2025. NOCFPS was Tk. (0.40) for January-March 2026 as against Tk. 0.08 for January-March 2025. NAV per share was Tk. (106.49) as on March 31, 2026 and Tk. (102.46) as on March 31, 2025.
PRIMEFIN: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. (0.61) for January-March 2024 as against Tk. (0.29) for January-March 2023. Consolidated NOCFPS was Tk. (0.30) for January-March 2024 as against Tk. (0.37) for January-March 2023. Consolidated NAV per share was Tk. 0.85 as on March 31, 2024 and Tk. 6.71 as on March 31, 2023.
DELTALIFE: Q1 Financials
(Q1 Un-audited): As per consolidated life revenue account of the company for the 1st Quarter ended on March 31, 2026: Balance of Life Insurance Fund was BDT 41,996.76 million as on March 31, 2026 as against BDT 39,560.76 million as on March 31, 2025. Net premium was BDT 2,269.05 million during January-March 2026 as against BDT 1,983.03 million during January-March 2025. Total expenses were BDT 2,201.47 million during January-March 2026 as against BDT 2,288.05 million during January-March 2025.
PRIMEFIN: Q1 Financials (Additional Information)
(Q1 Un-audited): Refer to their earlier news disseminated by DSE today i.e., 30.06.2026 regarding Q1 Financials, the company has further informed the reasons for deviation as follows: Q1 of 2024, interest income decreased because a few loans are classified in the month of Dec 2023 which has been impacted on the Q1 of the 2024 and the interest expense increased compared to Q1 2023 because the rate of interest on TDR is increased, resulting the Profit and EPS decreased. (cont.)
PRIMEFIN: Q2 Financials (Additional Information)
(Q2 Un-audited): Refer to their earlier news disseminated by DSE today i.e., 30.06.2026 regarding Q2 Financials, the company has further informed the reasons for deviation as follows: Q2 of 2024, interest income decreased because a few loans are classified in the month of Dec 2023 which has been impacted on the Q2 of the 2024 and the interest expense increased compared to Q2 2023 because (cont.)
PRIMEFIN: Q3 Financials (Additional Information)
(Q3 Un-audited): Refer to their earlier news disseminated by DSE today i.e., 30.06.2026 regarding Q3 Financials, the company has further informed the reasons for deviation as follows: Q3 of 2024, interest income decreased due to classification of loans increased and Interest expense on TDR is increased and provision for loan/advances increased compared to Q3 2023 resulting the Profit and EPS decreased. (cont.)
FIRSTFIN: Q1 Financials
(Q1 Un-audited): EPS was Tk. (1.87) for January-March 2026 as against Tk. (1.27) for January-March 2025. NOCFPS was Tk. (0.06) for January-March 2026 as against Tk. (0.09) for January-March 2025. NAV per share was Tk. (47.88) as on March 31, 2026 and Tk. (39.13) as on March 31, 2025.
MEGHNALIFE: Q1 Financials
(Q1 Un-audited): As per consolidated life revenue account of the company for January to March, 2026, excess of total expenses including claims over total income (deficit) was BDT 459.13 million as against excess of total expenses including claims over total income (deficit) of BDT 781.01 million in the corresponding previous period of 2025. (cont.)
BIFC: Q1 Financials (Revised)
Refer to their earlier news of Q1 Financials disseminated by DSE on 25.06.2026, the company has informed that there was an error in the reported NOCFPS figure in the PSI. The correct NOCFPS for January-March 2026 is Tk. 0.02 instead of Tk. (0.02). Other information will remain unchanged.
ISLAMICFIN: Q1 Financials
(Q1 Un-audited): EPS was Tk. (0.93) for January-March 2026 as against Tk. (0.62) for January-March 2025. NOCFPS was Tk. 0.10 for January-March 2026 as against Tk. (0.02) for January-March 2025. NAV per share was Tk. 1.46 as on March 31, 2026 and Tk. (0.42) as on March 31, 2025.
CLICL: Q1 Financials
As per life revenue account of the company for January to March, 2026, excess of total income over total expenses including claims (surplus) was BDT 13.75 million as against excess of total income over total expenses including claims (surplus) of BDT 28.51 million in the corresponding previous period of 2025. (cont.)
FASFIN: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. (5.16) for January-March 2026 as against Tk. (4.63) for January-March 2025. Consolidated NOCFPS was Tk. (0.23) for January-March 2026 as against Tk. (0.16) for January-March 2025. Consolidated NAV per share was Tk. (153.21) as on March 31, 2026 and Tk. (129.96) as on March 31, 2025. (cont.)
POPULARLIF: Q1 Financials
As per consolidated life revenue account of the company for the period ended March 31 2026, the total income was Tk. 1,001,371,036.00; total expense was Tk. 990,598,606.00 and Life Fund was Tk. 10,772,430.00 as against Tk. 1,020,665,558.00; Tk. 1,181,223,306.00 and Tk. (160,557,748.00) for the period ended March 31, 2025. NOCFPS was Tk. 27.66 for January-March 2026 as against Tk. 30.46 for January-March 2025.
CLICL: Q1 Financials (correction news)
The Balance of the Life Insurance Fund was BDT 666.48 million as on March 31, 2025, instead of March 31, 2024. Other information will remain unchanged.
POPULARLIF: Q1 Financials (Revised)
Refer to their earlier news disseminated by DSE today i.e., 28.06.2026 regarding Q1 Financials, the company has further informed that, as per consolidated life revenue account of the company for January to March, 2026, excess of total income over total expenses including claims (surplus) was BDT 10.77 million as against excess of total expenses including claims over total income (deficit) of BDT 160.56 million in the corresponding previous period of 2025. (cont.)
ISLAMIINS: Q1 Financials
(Q1 Un-audited): EPS was Tk. 1.02 for January-March 2026 as against Tk. 0.80 for January-March 2025. NOCFPS was Tk. 1.48 for January-March 2026 as against Tk. 0.12 for January-March 2025. NAV per share was Tk. 24.67 as on March 31, 2026 and Tk. 23.62 as on December 31, 2025.
BIFC: Q1 Financials
(Q1 Un-audited): EPS was Tk. (1.81) for January-March 2026 as against Tk. (1.65) for January-March 2025. NOCFPS was Tk. (0.02) for January-March 2026 as against Tk. (0.06) for January-March 2025. NAV per share was Tk. (135.39) as on March 31, 2026 and Tk. (127.76) as on March 31, 2025.
BXPHARMA: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 5.30 for July-September 2025 as against Tk. 3.77 for July-September 2024. Consolidated NOCFPS was Tk. 6.14 for July-September 2025 as against Tk. 3.80 for July-September 2024. Consolidated NAV per share was Tk. 124.34 as on September 30, 2025 and Tk. 111.25 as on September 30, 2024. Reasons for significant deviations: The notable growth in net revenue during the reporting quarter compared to the corresponding prior period, (cont.1)
BXPHARMA: Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 5.28 for October-December 2025 as against Tk. 4.10 for October-December 2024; Consolidated EPS was Tk. 10.58 for July-December 2025 as against Tk. 7.87 for July-December 2024. Consolidated NOCFPS was Tk. 11.16 for July-December 2025 as against Tk. 6.13 for July-December 2024. Consolidated NAV per share was Tk. 129.63 as on December 31, 2025 and Tk. 111.35 as on December 31,2024. Reasons for deviations: (cont.1)
BXPHARMA: Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 3.86 for January-March 2025 as against Tk. 3.06 for January-March 2024; Consolidated EPS was Tk. 11.73 for July 2024-March 2025 as against Tk. 9.75 for July 2023-March 2024. Consolidated NOCFPS was Tk. 9.46 for July 2024-March 2025 as against Tk. 14.79 for July 2023-March 2024. Consolidated NAV per share was Tk. 115.21 as on March 31, 2025 and Tk. 104.17 as on March 31, 2024.